Home - Products - Others - Other Targets - Succinate/succinate receptor antagonist 1

Succinate/succinate receptor antagonist 1

CAS No. 2361972-29-2

Succinate/succinate receptor antagonist 1( —— )

Catalog No. M36075 CAS No. 2361972-29-2

Succinate/succinate receptor antagonist 1 is a potent succinate receptor antagonist.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	52	Get Quote
5MG	76	Get Quote
10MG	132	Get Quote
25MG	266	Get Quote
50MG	419	Get Quote
100MG	605	Get Quote
500MG	1287	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Succinate/succinate receptor antagonist 1
Note

Research use only, not for human use.
Brief Description

Succinate/succinate receptor antagonist 1 is a potent succinate receptor antagonist.
Description

Succinate/succinate receptor antagonist 1 (compound 7a) is a succinate/succinate receptor antagonist. Succinate/succinate receptor antagonist 1 blocks succinate signaling in gingival tissue. Succinate/succinate receptor antagonist 1 inhibits the activation of succinate receptor 1 (SucnRl) with an IC50 value of 20 μΜ. Succinate/succinate receptor antagonist 1 can be used for the research of periodontal disease.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

Chemical Information

CAS Number

2361972-29-2
Formula Weight

277.32
Molecular Formula

C17H15N3O
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 25 mg/mL (90.15 mM; Ultrasonic )
SMILES

CNC(=O)Cc1ccc(cc1)-c1ccc2cccnc2n1
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. LI, Xin, et al. PERIODONTAL DISEASE THERAPY. WO2019136022. 2020.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Vazegepant HCl

Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.
Thioacetazone

Thioacetazone is a thiosemicarbazone that?thioacetazone treatment of pulmonary tuberculosis.
Ciamexon

Ciamexon (Ciamexone) is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.

Sign In Join Free